PHOENIX, AZ--(Marketwired - March 24, 2014) - Today, at the Society of Toxicology's 53rd Annual Meeting, Hepregen Corporation, a leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based in vitro assay products announced the commercial launch of the company's first HepatoPac™ kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates. The application-directed platform also provides a tool for the study of the mechanisms leading to such responses.
Jack McGeehan, Hepregen's Vice President of Operations, stated, "The hepatocytes in this specially configured product remain viable for weeks at a time, and they exhibit full functionality during this extended time period. This longevity means that the product may be useful for the study of chronic exposure to drug candidates and other new chemical entities, reflecting what likely could occur when humans are exposed to such agents for long periods. Because the hepatocytes also are fully active metabolically, investigators can evaluate toxicity associated with metabolites of these chemical entities in a single experiment."
Dr. Vincent Zurawski, Hepregen's Chief Executive Officer, stated, "This new kit is the first version of a human HepatoPac™ application-directed kit that is focused on the in vitro toxicology market. In the coming months, aiming to serve this growing market, Hepregen also expects to be introducing more advanced HepatoPac™ toxicology products, some of which are currently in development. The launch adds another product to the company's portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPac™ application-directed kits for metabolite identification and profiling, and a recently introduced human kit to evaluate metabolic stability."
About Hepregen Corporation
Hepregen Corporation is a leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and product development in the pharmaceutical and biopharmaceutical, diagnostic, cosmetics, and chemical industries. The company's micro-liver HepatoPac™ and HepatoMune™ cell-based assays are intended to drive a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™ and HepatoMune™ application-directed products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures and Innovation Valley Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements. Such forward-looking statements reflect Hepregen Corporation's expectations about its future operating results, performance and opportunities that involve substantial risk and uncertainties. These statements include but are not limited to statements regarding the performance and results of the company's HepatoPac™ application-directed kits. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target," "intend" and "expect" and similar expressions, as they relate to Hepregen Corporation or its management are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to Hepregen Corporation and are subject to a number of risks, uncertainties and other factors that could cause Hepregen Corporation's actual results, performance, prospects and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Image Available: http://www.marketwire.com/library/MwGo/2014/3/24/11G013657/Images/Tox_Hexagon-470516220689.jpg